These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 26222558)

  • 21. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
    Gelderblom H; Razak AA; Taylor MH; Bauer TM; Wilky B; Martin-Broto J; Gonzalez AF; Rutkowski P; Szostakowski B; Alcindor T; Saleh R; Genta S; Stacchiotti S; van de Sande M; Wagner AJ; Bernthal N; Davis LE; Vuky J; Tait C; Matin B; Narasimhan S; Sharma MG; Ruiz-Soto R; Sherman ML; Tap WD
    Clin Cancer Res; 2024 Sep; 30(18):3996-4004. PubMed ID: 38995311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene.
    Brahmi M; Alberti L; Tirode F; Karanian M; Eberst L; Pissaloux D; Cassier P; Blay JY
    Ann Oncol; 2018 Jun; 29(6):1488-1489. PubMed ID: 29668829
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
    Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
    Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
    Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
    Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.
    Giustini N; Bernthal NM; Bukata SV; Singh AS
    Clin Sarcoma Res; 2018; 8():14. PubMed ID: 30002809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.
    Sikaria S; Heim-Hall J; Diaz EH; Williams R; Sankhala K; Laabs B; Mita M
    Target Oncol; 2014 Mar; 9(1):73-9. PubMed ID: 23430345
    [No Abstract]   [Full Text] [Related]  

  • 27. [Tenosynovial giant cell tumor].
    Kuhnen C; Müller KM; Rabstein S; Kasprzynski A; Herter P
    Pathologe; 2005 Mar; 26(2):96-110. PubMed ID: 15657685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue.
    Sugita S; Takenami T; Kido T; Aoyama T; Hosaka M; Segawa K; Sugawara T; Fujita H; Shimizu J; Murahashi Y; Emori M; Hasegawa T
    Diagn Pathol; 2022 Nov; 17(1):88. PubMed ID: 36320082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
    Smeester BA; Slipek NJ; Pomeroy EJ; Laoharawee K; Osum SH; Larsson AT; Williams KB; Stratton N; Yamamoto K; Peterson JJ; Rathe SK; Mills LJ; Hudson WA; Crosby MR; Wang M; Rahrmann EP; Moriarity BS; Largaespada DA
    Bone; 2020 Jul; 136():115353. PubMed ID: 32251854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors.
    Ho J; Peters T; Dickson BC; Swanson D; Fernandez A; Frova-Seguin A; Valentin MA; Schramm U; Sultan M; Nielsen TO; Demicco EG
    Genes Chromosomes Cancer; 2020 Feb; 59(2):96-105. PubMed ID: 31469468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
    Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
    Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
    Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
    Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.
    Shankarappa PS; Peer CJ; Odabas A; McCully CL; Garcia RC; Figg WD; Warren KE
    Cancer Chemother Pharmacol; 2020 May; 85(5):1003-1007. PubMed ID: 32306101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
    BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytologic findings in tenosynovial giant cell tumors investigated by fine-needle aspiration cytology.
    Layfield LJ; Moffatt EJ; Dodd LG; Scully SP; Harrelson JM
    Diagn Cytopathol; 1997 Apr; 16(4):317-25. PubMed ID: 9143824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
    Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
    Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.
    Cheng H; Clarkson PW; Gao D; Pacheco M; Wang Y; Nielsen TO
    Sarcoma; 2010; 2010():174528. PubMed ID: 20981142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The growing problem of benign connective tissue tumours.
    Thomas DM
    Lancet Oncol; 2015 Aug; 16(8):879-80. PubMed ID: 26179199
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.